KR102372615B1 - 백신 조성물 및 그의 용도 - Google Patents

백신 조성물 및 그의 용도 Download PDF

Info

Publication number
KR102372615B1
KR102372615B1 KR1020177032987A KR20177032987A KR102372615B1 KR 102372615 B1 KR102372615 B1 KR 102372615B1 KR 1020177032987 A KR1020177032987 A KR 1020177032987A KR 20177032987 A KR20177032987 A KR 20177032987A KR 102372615 B1 KR102372615 B1 KR 102372615B1
Authority
KR
South Korea
Prior art keywords
crm
alum
neu
pro
crm197
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177032987A
Other languages
English (en)
Korean (ko)
Other versions
KR20180003560A (ko
Inventor
우르술라 비데르만
Original Assignee
바이오라이프 사이언스 큐엘디 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901375A external-priority patent/AU2015901375A0/en
Application filed by 바이오라이프 사이언스 큐엘디 리미티드 filed Critical 바이오라이프 사이언스 큐엘디 리미티드
Publication of KR20180003560A publication Critical patent/KR20180003560A/ko
Application granted granted Critical
Publication of KR102372615B1 publication Critical patent/KR102372615B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177032987A 2015-04-17 2016-04-15 백신 조성물 및 그의 용도 Active KR102372615B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901375A AU2015901375A0 (en) 2015-04-17 A vaccine composition and uses thereof
AU2015901375 2015-04-17
PCT/AU2016/050275 WO2016164980A1 (en) 2015-04-17 2016-04-15 A vaccine composition and uses thereof

Publications (2)

Publication Number Publication Date
KR20180003560A KR20180003560A (ko) 2018-01-09
KR102372615B1 true KR102372615B1 (ko) 2022-03-08

Family

ID=57125491

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177032987A Active KR102372615B1 (ko) 2015-04-17 2016-04-15 백신 조성물 및 그의 용도

Country Status (13)

Country Link
US (1) US10532090B2 (https=)
EP (1) EP3283105B1 (https=)
JP (1) JP6957448B2 (https=)
KR (1) KR102372615B1 (https=)
CN (1) CN108025061B (https=)
AU (1) AU2016250289B2 (https=)
ES (1) ES2908071T3 (https=)
NZ (1) NZ736194A (https=)
RS (1) RS63080B1 (https=)
RU (1) RU2726411C2 (https=)
SG (1) SG11201708247XA (https=)
TW (1) TWI740823B (https=)
WO (1) WO2016164980A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346484A1 (en) * 2017-12-11 2021-11-11 Medizinische Universitaet Wien Method of producing a vaccine composition and uses thereof
WO2019153042A1 (en) * 2018-02-07 2019-08-15 Imugene Limited A vaccine composition and uses thereof
US20240027434A1 (en) * 2020-12-16 2024-01-25 Dynavax Technologies Corporation Method for quantifying cpg-containing oligonucleotides in compositions comprising alum

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011020604A1 (en) * 2009-08-18 2011-02-24 Pevion Biotech Ag Multiepitope vaccine for her2/neu-associated cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739984A1 (en) * 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP1246597B1 (en) * 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
EP1236740B1 (de) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
ES2348312T3 (es) 2006-04-13 2010-12-02 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna her-2/neu a base de múltiples péptidos.
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
DK2668959T3 (en) * 2012-05-31 2015-01-26 Innavirvax Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
EP3166646A4 (en) * 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011020604A1 (en) * 2009-08-18 2011-02-24 Pevion Biotech Ag Multiepitope vaccine for her2/neu-associated cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Acc. Chem. Res. 제48권, 643-652면(2015.2.10)*
Braz J Med Biol Res., 제45권 제8호 681-692면(2012)*

Also Published As

Publication number Publication date
CN108025061B (zh) 2022-02-15
NZ736194A (en) 2022-08-26
KR20180003560A (ko) 2018-01-09
US10532090B2 (en) 2020-01-14
EP3283105B1 (en) 2022-01-26
TW201705978A (zh) 2017-02-16
RS63080B1 (sr) 2022-04-29
EP3283105A4 (en) 2018-12-19
EP3283105A1 (en) 2018-02-21
WO2016164980A1 (en) 2016-10-20
TWI740823B (zh) 2021-10-01
AU2016250289A1 (en) 2017-01-05
AU2016250289B2 (en) 2017-03-02
ES2908071T3 (es) 2022-04-27
CN108025061A (zh) 2018-05-11
RU2726411C2 (ru) 2020-07-14
HK1248536A1 (zh) 2018-10-19
RU2017137502A3 (https=) 2019-09-16
JP6957448B2 (ja) 2021-11-02
RU2017137502A (ru) 2019-05-17
BR112017021981A2 (pt) 2018-07-10
JP2018511659A (ja) 2018-04-26
SG11201708247XA (en) 2017-11-29
US20170119867A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
US10166276B2 (en) Compositions and methods for treatment of non-hodgkins lymphoma
US20170143810A1 (en) Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
KR102372615B1 (ko) 백신 조성물 및 그의 용도
CN112203681B (zh) 疫苗组合物及其用途
CN111295200B (zh) 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
US20180264093A1 (en) Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
US20210346484A1 (en) Method of producing a vaccine composition and uses thereof
AU2014296038B2 (en) Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
KR102893870B1 (ko) 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
BR112017021981B1 (pt) Composição de vacina e usos da mesma
HK1248536B (en) A vaccine composition and uses thereof
WO2026046055A1 (en) Pharmaceutical compositions and methods for preventing or treating cancers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171114

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210122

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20210122

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210524

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210924

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210524

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210924

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210723

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210122

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220102

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20211126

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210924

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210723

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210122

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220304

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220304

End annual number: 3

Start annual number: 1

PG1601 Publication of registration